Who are Pfizer-BioNTech COVID-19 mRNA vaccine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): PF-07321332 Dose 5, Paxlovid (Copackaged), Comirnaty, Veklury, Influenza, Part A: ATM-AVI Single Dose, Cohorts 1-4.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/pfizer-biontech-covid-19-mrna-vaccine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Pfizer-BioNTech COVID-19 mRNA vaccine — Competitive Intelligence Brief

Pfizer-BioNTech COVID-19 mRNA vaccine (Pfizer-BioNTech COVID-19 mRNA vaccine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: vaccine. Area: Immunology.

marketed vaccine SARS-CoV-2 Immunology Biologic Live · refreshed every 30 min

Target snapshot

Pfizer-BioNTech COVID-19 mRNA vaccine (Pfizer-BioNTech COVID-19 mRNA vaccine) — Pfizer. mRNA vaccine that uses a piece of genetic material to instruct cells to produce a protein that triggers an immune response

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Pfizer-BioNTech COVID-19 mRNA vaccine TARGET	Pfizer-BioNTech COVID-19 mRNA vaccine	Pfizer	marketed	vaccine	SARS-CoV-2
PF-07321332 Dose 5	pf-07321332-dose-5	Pfizer	marketed	Protease inhibitor	Main protease (MPro) of SARS-CoV-2	Pending regulatory approval
Paxlovid (Copackaged)	Nirmatrelvir	Pfizer	marketed	Antiviral protease inhibitor	SARS-CoV-2 main protease (Mpro, 3CLpro, nsp5 protease)	2023-01-01
Comirnaty	BNT162b2 (tozinameran)	Pfizer Inc.	marketed	vaccine	SARS-CoV-2 virus	2021-08-23
Veklury	remdesivir	Gilead Sciences	marketed	Nucleotide analog RNA polymerase inhibitor	SARS-CoV-2 RNA polymerase	2020-01-01
Influenza	Influenza and COVID-19 Combination A	BioNTech	marketed	Non-Standardized Plant Allergenic Extract [EPC]	SARS-CoV-2 spike protein and influenza hemagglutinin protein
Part A: ATM-AVI Single Dose, Cohorts 1-4	part-a-atm-avi-single-dose-cohorts-1-4	Pfizer	marketed	Monoclonal antibody	Spike protein of SARS-CoV-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2041-08-05 — Paxlovid (Copackaged) · 11351149 · US
2041-10-31 — Paxlovid (Copackaged) · 11541034 · US

Sponsor landscape (vaccine class)

Pfizer · 20 drugs in this class
Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
GlaxoSmithKline · 12 drugs in this class
Merck Sharp & Dohme LLC · 12 drugs in this class
Centers for Disease Control and Prevention · 9 drugs in this class
Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
Beijing Center for Disease Control and Prevention · 6 drugs in this class
International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
Sinovac Biotech Co., Ltd · 4 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Pfizer-BioNTech COVID-19 mRNA vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/pfizer-biontech-covid-19-mrna-vaccine. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab